December 3, 2018
Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting
Stockholm – December 3, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflu...
Read more
Read more
December 2, 2018
Nordic Nanovector: Single administration Betalutin® is effective and well-tolerated in R/R iNHL patients: 6 month follow-up data presented at ASH
02.12.2018 18:10
Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin’s lymphoma (iNHL)
Highly activ...
Read more
Read more
December 2, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
December 2, 2018—BOSTON, MA. and STOCKHOLM, SWEDEN, November 30, 2018 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeti...
Read more
Read more
December 2, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
December 2, 2018—
95% ORR (by IWG) in 20 evaluable patients
70% complete remission (CR) rate in 20 evaluable patients
No do...
Read more
Read more
December 1, 2018
Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting
December 1, 2018 - Regulatory press release Press releases
Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentati...
Read more
Read more
November 30, 2018
US Court of Appeals denies Actavis’s petition for rehearing regarding validity of the Zubsolv® patent
Uppsala, Sweden – November 30, 2018 – Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC’s (Actavis) ...
Read more
Read more
November 30, 2018
Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02
Mölndal, 30 November 2018 – The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore Pharma”, or the ”Company”) has resolved, subject to the approval by an Ext...
Read more
Read more
November 28, 2018
Targovax is invited to present at upcoming investor and industry conferences
Oslo, Norway, 28 November 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that ...
Read more
Read more
November 27, 2018
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
GAITHERSBURG, Md., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Ga...
Read more
Read more
November 27, 2018
BioClin Therapeutics Announces Name Change to Rainier Therapeutics
SAN LEANDRO, Calif., November 27 2018— BioClin Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need of ...
Read more
Read more